Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Garo Armen

Agenus Inc.

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Alphamab Oncology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Metric
Company Name	Sierra Oncology	Agenus Inc.	Alphamab Oncology	Barinthus Biotherapeutics plc
Symbol		AGEN	9.97K	BRNS
MSH ID	COM:SIERRAONCOLOGY	COM:AGENUSBIO	COM:ALPHAMABONC	COM:BARINTHUSBIO
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Biotechnology
Country	GB	US	CN	GB
Stage
Employee Count		389	435	130
Website	sierraoncology.com	agenusbio.com	alphamabonc.com	barinthusbio.com
LinkedIn
Founders

Metric
Market Cap	321.29M	286.50M	55.90M
Enterprise Value
Monthly Web Traffic	1.43K
Web Traffic Growth	0.48
Valuation
Raised Capital

Metric
Revenue	156.31M	30.09M	802K
Revenue (LTM)
Revenue (NTM)
Gross Profit	139.62M	22.49M	802K
EBITDA	-146.52M	-38.90M	-83.91M
Operating Income	-160.10M	-44.47M	-83.91M
Net Income	-245.76M	-28.97M	-73.35M
EPS	-0.69	-0.03	-1.91K
Diluted EPS	-0.69	-0.03	-1.91K
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.62	0.79	0.19
Operating Profit Margin	-0.71	-1.11	-10.38
EBITDA Margin	-0.94	-1.29	-104.63
Net Profit Margin	-1.40	-0.84	-11.91
Return on Equity	2.26	-0.12	-0.35
Return on Assets	-0.76	-0.09	-0.34
Return on Capital Employed	-2.75	-0.16	-0.33

COM:SIERRAONCOLOGY

Sierra Oncology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.80	-10.08	-1.22
P/B Ratio	-1.87	2.13	0.48
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.29	21.63	116.13
EV Multiple	2.30	-10.19	-2.39

Metric
Days Sales Outstanding	3.73		2.23K
Days Payables Outstanding	64.39	62.85	128.91
Days Inventory Outstanding	0.00	520.35	0.00
Operating Cycle	60.33	532.25	2.23K
Cash Conversion Cycle	-66.99	352.76	2.10K
Asset Turnover	0.63	0.12	0.03

Metric
Operating Cash Flow	-224.20M		-50.92M
Free Cash Flow	-234.16M		-50.92M
Cash Flow to Debt	-0.51	-0.29	-3.92
Operating Cash Flow/Sales	-0.90	-0.34	-10.17
Free Cash Flow Yield	-0.99	-0.13	-0.63

Metric
Cash & Equivalents	76.11M	149.37M	142.09M
Accounts Receivable	-23.46M
Inventory		10.83M
Goodwill	24.72M		12.21M
Debt to Capitalization	3.38	0.16	0.07
Debt to Assets	0.27	0.16	0.06
Current Ratio	0.63	3.88	12.45
Quick Ratio	0.40	6.14	11.67

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.21	0.08	6.30
R&D to Revenue	0.25	2.81	56.05
SG&A to Revenue	0.82	0.52	49.68